Tyrosinaemia type I and NTBC (2‐(2‐nitro‐4‐trifluoromethylbenzoyl)‐1,3‐cyclohexanedione)

Holme, E.; Lindstedt, S.

doi:10.1023/a:1005410820201

Cited by 265Metabolism and Genetic DisordersAmino Acid Enzymes and MetabolismNeonatal Health and Biochemistry

Tyrosinaemia type I and NTBC (2‐(2‐nitro‐4‐trifluoromethylbenzoyl)‐1,3‐cyclohexanedione)

Holme, E., Lindstedt, S.·1998·Journal of Inherited Metabolic Disease

DOI 10.1023/a:1005410820201

Open this paper in CoChat — free account

Abstract

In tyrosinaemia type I (McKusick 276700), fatal liver disease results either because of liver failure during infancy or early childhood or because of development of hepatocellular carcinoma during childhood or adolescence. This is caused by toxic metabolites which accumulate because of deficiency of fumarylacetoacetase, the last enzyme in the tyrosine catabolic pathway. NTBC is a potent inhibitor of 4‐hydroxyphenylpyruvate dioxygenase and has been shown to efficiently prevent tyrosine degradation, and production of succinylacetone, in patients with tyrosinaemia. Since the first trial of NTBC treatment for tyrosinaemia type I in 1991, over 220 patients have been treated by the drug using a protocol which includes regular follow‐up with reports of clinical and laboratory investigations to the study centre in Gothenburg, where additional analysis of critical variables is done on regularly collected samples. The course of the disease in patients with acute tyrosinaemia has changed dramatically. Only 10% of the patients have not clinically responded to NTBC treatment. In half of these patients, successful liver transplantation has been performed which has further reduced the mortality rate during infancy to 5%. The international NTBC study has now been going for 5 years and data have emerged that indicate a decreased risk for early development of hepatocellular carcinoma in patients who started treatment at an early age. There are now 101 patients aged 2–8 years who have started NTBC treatment before 2 years of age, and no cancer has developed after 2 years of age among these patients. However, there is no safe age with respect to occurrence of liver cancer, which has been recognized at diagnosis at 1 year of age in one patient and after a few months of treatment in an infant who was given NTBC at 5 months of age.

Integrity signals

Registry

Crossref · 10.1023/a:1005410820201

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Eye complications do not appear to be common in HT1.
“Eye complications do not appear to be common [16,39] but periodic eye examination with a slit lamp may be indicated (for example annually).”
From Recommendations for the management of tyrosinaemia type 1 (2013) · cites this paper as [16]
Plasma nitisinone concentrations in individuals are variable.
“As the plasma concentrations in individuals are variable [16], if rapid assay of plasma nitisinone level is available it may be useful in detecting problems.”
From Recommendations for the management of tyrosinaemia type 1 (2013) · cites this paper as [16]
On standard nitisinone dose 1 mg/kg/d, plasma concentrations that suppress succinylacetone are variable between individuals.
“On the standard dose of 1 mg/kg/d, the plasma concentrations in individuals that suppress SA are variable [16,20].”
From Recommendations for the management of tyrosinaemia type 1 (2013) · cites this paper as [16]
Nitisinone reduces the risk of long term complications.
“The risk of long term complications is also reduced [16].”
From Recommendations for the management of tyrosinaemia type 1 (2013) · cites this paper as [16]

Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase
LINDSTEDT, S. (1992) · The Lancet · doi:10.1016/0140-6736(92)92685-9 · Cited by 631 · see citing works
Self-citation
On the enzymic defects in hereditary tyrosinemia.
Lindblad, B., Lindstedt, S., & Steen, G. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.10.4641 · Cited by 447 · see citing works
Self-citation
Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I
Grompe, M., Lindstedt, S., Al-Dhalimy, M., Kennaway, N. G., Papaconstantinou, J., Torres-Ramos, C. A., Ou, C.-N., & Finegold, M. (1995) · Nature Genetics · doi:10.1038/ng0895-453 · Cited by 312 · see citing works
Self-citation
The occurrence of hepatoma in the chronic form of hereditary tyrosinemia
Weinberg, A. G., Mize, C. E., & Worthen, H. G. (1976) · The Journal of Pediatrics · doi:10.1016/s0022-3476(76)80259-4 · Cited by 283 · see citing works
Neurologic Crises in Hereditary Tyrosinemia
Mitchell, G. A., Larochelle, J., Lambert, M. A., Michaud, J., Grenier, A., de Baulny, H. O., Gauthier, M., Lacroix, J., Vanasse, M., Larbrisseau, A., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199002153220704 · Cited by 230 · see citing works
Hereditary Tyrosinemia Type I: A New Clinical Classification With Difference in Prognosis on Dietary Treatment
Van Spronsen, F. J., Thomasse, Y., Smit, P. G. A., Leonard, J. V., Clayton, P. T., Fidler, V., Berger, R., & Heymans, H. S. A. (1994) · Hepatology · doi:10.1002/hep.1840200513 · Cited by 193 · see citing works
Self-induced correction of the genetic defect in tyrosinemia type I.
Kvittingen, E. A., Rootwelt, H., Berger, R., & Brandtzaeg, P. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117509 · Cited by 168 · see citing works
Inhibition of 4-Hydroxyphenylpyruvate Dioxygenase by 2-(2-Nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione and 2-(2-Chloro-4-methanesulfonylbenzoyl)-cyclohexane-1,3-dione
Ellis, M. K., Whitfield, A. C., Gowans, L. A., Auton, T. R., Provan, W. M., Lock, E. A., & Smith, L. L. (1995) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1995.1121 · Cited by 114 · see citing works
From toxicological problem to therapeutic use: The discovery of the mode of action of 2‐(2‐nitro‐4‐trifluoromethylbenzoyl)‐1,3‐cyclohexanedione (NTBC), its toxicology and development as a drug
Lock, E. A., Ellis, M. K., Gaskin, P., Robinson, M., Auton, T. R., Provan, W. M., Smith, L. L., Prisbylla, M. P., Mutter, L. C., & Lee, D. L. (1998) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1005458703363 · Cited by 108 · see citing works
Hereditary tyrosinemia type I: Self-induced correction of the fumarylacetoacetase defect
Kvittingen, E. A., Rootwelt, H., Brandtzaeg, P., Bergan, A., & Berger, R. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116393 · Cited by 102 · cited 2× · see citing works
“In older patients, the low production may in part be due to self-induced correction of the fumarylacetoacetase defect (Kvittingen et al 1993, 1994), which has been documented to occur in nodules of regenerative liver tissue.”
Background
Diagnosis and management of tyrosinemia type I
Holme, E., & Lindstedt, S. (1995) · The Journal of Pediatrics · doi:10.1097/00008480-199512000-00017 · Cited by 65 · see citing works
Self-citation
Complete Rescue of Lethal Albino c Mice by Null Mutation of 4-Hydroxyphenylpyruvate Dioxygenase and Induction of Apoptosis of Hepatocytes in These Mice by in VivoRetrieval of the Tyrosine Catabolic Pathway
Endo, F., Kubo, S., Awata, H., Kiwaki, K., Katoh, H., Kanegae, Y., Saito, I., Miyazaki, J., Yamamoto, T., Jakobs, C., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.39.24426 · Cited by 63 · see citing works
Steady state kinetics of 4-hydroxyphenylpyruvate dioxygenase from human liver (III).
Rundgren, M. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40162-1 · Cited by 41 · see citing works
Tyrosinaemia Type I: Orthotopic Liver Transplantation as the Only Definitive Answer to a Metabolic as well as an Oncological Problem
van Spronsen, F. J., Berger, R., Smit, G., de Klerk, J. B. C., Durán, M., Bijleveld, C. M. A., van Faassen, H., Slooff, M. J. H., & Heymans, H. S. A. (1989) · Journal of Inherited Metabolic Disease · doi:10.1007/bf03335416 · Cited by 35 · see citing works
Peripheral neuropathy as the presenting feature of tyrosinaemia type I and effectively treated with an inhibitor of 4-hydroxyphenylpyruvate dioxygenase.
Gibbs, T., Payan, J., Brett, E. M., Lindstedt, S., Holme, E., & Clayton, P. T. (1993) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.56.10.1129 · Cited by 29 · see citing works
Self-citation
Liver transplantation in nine Spanish patients with tyrosinaemia type I
Pérez‐Cerdá, C., Merinero, B., Sanz, P., Castro, M., Gangoiti, J. A., García, M. J., Díaz, M., Medina, E. M. E., & Ugarte, M. (1995) · Journal of Inherited Metabolic Disease · doi:10.1007/bf00711744 · Cited by 20 · see citing works
Treatment of two children with hereditary tyrosinaemia type I and long‐standing renal disease with a 4‐hydroxyphenylpyruvate dioxygenase inhibitor (NTBC)
Pronicka, E., Rowińska, E., Bentkowski, Z. A., Zawadzki, J., Holme, E., & Lindstedt, S. (1996) · Journal of Inherited Metabolic Disease · doi:10.1007/bf01799438 · Cited by 16 · see citing works
Self-citation

Flagged first, then by citations

Sorted by citations

AASLD practice guidelines
Murray, K. F., & Carithers, R. L. (2005) · Hepatology · doi:10.1002/hep.20704 · Cited by 933 · see citing works
Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency
Knisely, A. S., Strautnieks, S. S., Meier, Y., Stieger, B., Byrne, J. A., Portmann, B. C., Bull, L. N., Pawlikowska, L., Bilezikçi, B., Özçay, F., et al. (2006) · Hepatology · doi:10.1002/hep.21287 · Cited by 377 · see citing works
4-Hydroxyphenylpyruvate dioxygenase
Moran, G. R. (2005) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2004.08.015 · Cited by 306 · see citing works
Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations
Chinsky, J. M., Singh, R., Ficicioglu, C., van Karnebeek, C. D. M., Grompe, M., Mitchell, G., Waisbren, S. E., Gucsavas-Calikoglu, M., Wasserstein, M. P., Coakley, K., et al. (2017) · Genetics in Medicine · doi:10.1038/gim.2017.101 · Cited by 247 · see citing works
Recommendations for the management of tyrosinaemia type 1
de Laet, C., Dionisi-Vici, C., Leonard, J. V., McKiernan, P., Mitchell, G., Monti, L., de Baulny, H. O., Pintos-Morell, G., & Spiekerkötter, U. (2013) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-8-8 · Cited by 227 · see citing works
Tyrosinemia: A Review
Russo, P., Mitchell, G. A., & Tanguay, R. M. (2001) · Pediatric and Developmental Pathology · doi:10.1007/s100240010146 · Cited by 222 · see citing works
Population history and its impact on medical genetics in Quebec
Laberge, A., Michaud, J. L., Richter, A. M., Lemyre, E., Lambert, M. A., Brais, B., & Mitchell, G. A. (2005) · Clinical Genetics · doi:10.1111/j.1399-0004.2005.00497.x · Cited by 201 · see citing works
A 3-year randomized therapeutic trial of nitisinone in alkaptonuria
Introne, W. J., Perry, M. B., Troendle, J. F., Tsilou, E. T., Kayser, M. A., Suwannarat, P., O'Brien, K. E., Bryant, J. C., Sachdev, V., Reynolds, J. C., et al. (2011) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2011.04.016 · Cited by 201 · see citing works
Newborn Screening Fact Sheets
Kaye, C. I. (2006) · PEDIATRICS · doi:10.1542/peds.2006-1783 · Cited by 185 · see citing works
A journey of hope: lessons learned from studies on rare diseases and orphan drugs
Wästfelt, M., Fadeel, B., & Henter, J. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01666.x · Cited by 184 · see citing works
The genetic tyrosinemias
Scott, C. R. (2006) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.30092 · Cited by 184 · see citing works
NTBC treatment in tyrosinaemia type I: Long‐term outcome in French patients
Masurel‐Paulet, A., Poggi‐Bach, J., Rolland, M. ‐., Bernard, O., Guffon, N., Dobbelaere, D., Sarles, J., de Baulny, H. O., & Touati, G. (2008) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-008-0793-1 · Cited by 212 · see citing works
The pathophysiology and treatment of hereditary tyrosinemia type 1
Grompe, M. (2001) · Seminars in Liver Disease · doi:10.1055/s-2001-19035 · Cited by 167 · see citing works
Use of nitisinone in patients with alkaptonuria
Suwannarat, P., O’Brien, K., Perry, M. B., Sebring, N. G., Bernardini, I. M., Kaiser‐Kupfer, M. I., Rubin, B. I., Tsilou, E., Gerber, L. H., & Gahl, W. A. (2005) · Metabolism · doi:10.1016/j.metabol.2004.12.017 · Cited by 162 · see citing works
NONTRANSPLANT TREATMENT OF TYROSINEMIA
Holme, E., & Lindstedt, S. (2000) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70142-2 · Cited by 159 · see citing works
Self-citation
Nitisinone in the Treatment of Hereditary Tyrosinaemia Type 1
McKiernan, P. J. (2006) · Drugs · doi:10.2165/00003495-200666060-00002 · Cited by 151 · see citing works
Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Québec
Larochelle, J., Alvarez, F., Bussières, J.-F., Chevalier, I., Dallaire, L., Dubois, J., Faucher, F., Fenyves, D., Goodyer, P., Grenier, A., et al. (2012) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2012.05.022 · Cited by 137 · see citing works
Self-citation
Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice
Mayorandan, S., Meyer, U., Gokcay, G., Segarra, N. G., de Baulny, H. O., van Spronsen, F., Zeman, J., de Laet, C., Spiekerkoetter, U., Thimm, E., et al. (2014) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-014-0107-7 · Cited by 131 · see citing works
Reprogramming metabolic pathways in vivo with CRISPR/Cas9 genome editing to treat hereditary tyrosinaemia
Pankowicz, F. P., Barzi, M., Legras, X. D., Hubert, L., Tian, M., Tomolonis, J., Ravishankar, M., Sun, Q., Yang, D., Borowiak, M., et al. (2016) · Nature Communications · doi:10.1038/ncomms12642 · Cited by 134 · see citing works
Phenylketonuria: tyrosine supplementation in phenylalanine-restricted diets
van Spronsen, F. J., van Rijn, M., Bekhof, J., Koch, R., & Smit, P. (2001) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/73.2.153 · Cited by 114 · see citing works
4-Hydroxyphenylpyruvate Dioxygenase and Its Inhibition in Plants and Animals: Small Molecules as Herbicides and Agents for the Treatment of Human Inherited Diseases
Santucci, A., Bernardini, G., Braconi, D., Petricci, E., & Manetti, F. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01395 · Cited by 112 · see citing works
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Follow-Up Testing for Metabolic Disease Identified by Expanded Newborn Screening Using Tandem Mass Spectrometry; Executive Summary
Dietzen, D. J., Rinaldo, P., Whitley, R. J., Rhead, W. J., Hannon, W. H., Garg, U. C., Lo, S. F., & Bennett, M. J. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2009.131300 · Cited by 104 · see citing works
Newborn screening for hepatorenal tyrosinemia by tandem mass spectrometry: analysis of succinylacetone extracted from dried blood spots
Allard, P., Grenier, A., Korson, M. S., & Zytkovicz, T. H. (2004) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2004.07.006 · Cited by 99 · see citing works
Approaches to acute liver failure in children
Dhawan, A. K., Cheeseman, P., & Mieli‐Vergani, G. (2004) · Pediatric Transplantation · doi:10.1111/j.1399-3046.2004.00292.x · Cited by 94 · see citing works
Acute Liver Failure in Children
Bucuvalas, J. C., Yazigi, N. A., & Squires, R. H. (2006) · Clinics in Liver Disease · doi:10.1016/j.cld.2005.10.006 · Cited by 87 · see citing works
Long‐term therapy with NTBC and tyrosine‐restricted diet in a murine model of hereditary tyrosinemia type I
Al-Dhalimy, M., Overturf, K., Finegold, M., & Grompe, M. (2002) · Molecular Genetics and Metabolism · doi:10.1006/mgme.2001.3266 · Cited by 86 · see citing works
Diagnosis and early management of inborn errors of metabolism presenting around the time of birth1
Leonard, J. V., & Morris, A. A. M. (2005) · Acta Paediatrica · doi:10.1080/08035250500349413 · Cited by 85 · see citing works
The Cost-Effectiveness of Expanding Newborn Screening for up to 21 Inherited Metabolic Disorders Using Tandem Mass Spectrometry: Results from a Decision-Analytic Model
Cipriano, L. E., Rupar, C. A., & Zaric, G. S. (2007) · Value in Health · doi:10.1111/j.1524-4733.2006.00156.x · Cited by 82 · see citing works
Impaired Cognitive Functioning in Patients with Tyrosinemia Type I Receiving Nitisinone
Bendadi, F., de Koning, T. J., Visser, G., Prinsen, H. C. M. T., der Velden, M. G. M. D. S., Verhoeven‐Duif, N. M., Sinnema, G., van Spronsen, F. J., & van Hasselt, P. M. (2013) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2013.10.001 · Cited by 81 · see citing works
Neurocognitive outcome in patients with hypertyrosinemia type I after long‐term treatment with NTBC
Thimm, E., Richter‐Werkle, R., Kamp, G., Molke, B., Herebian, D., Klee, D., Mayatepek, E., & Spiekerkoetter, U. (2012) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-011-9394-5 · Cited by 79 · see citing works
Inhibition of Glutathione S-Transferase ζ and Tyrosine Metabolism by Dichloroacetate: A Potential Unifying Mechanism for Its Altered Biotransformation and Toxicity
Cornett, R., James, M. O., Henderson, G. N., Cheung, J., Shroads, A. L., & Stacpoole, P. W. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1287 · Cited by 74 · see citing works
Inborn errors of metabolism around time of birth
Leonard, J. V., & Morris, A. A. M. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02591-5 · Cited by 73 · see citing works
Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1
Santra, S., & Baumann, U. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.7.1229 · Cited by 68 · see citing works
Gene editing and its applications in biomedicine
Li, G., Li, X., Zhuang, S., Wang, L., Zhu, Y., Chen, Y., Sun, W. C., Wu, Z., Zhou, Z. L., Chen, J., et al. (2022) · Science China Life Sciences · doi:10.1007/s11427-021-2057-0 · Cited by 65 · see citing works
Frequent mutation reversion inversely correlates with clinical severity in a genetic liver disease, hereditary tyrosinemia
Demers, S. I., Russo, P., Lettre, F., & Tanguay, R. M. (2003) · Human Pathology · doi:10.1016/s0046-8177(03)00406-4 · Cited by 67 · see citing works
Clinical utility of nitisinone for the treatment of hereditary tyrosinemia type-1 (HT-1)
Das, A. M. (2017) · The Application of Clinical Genetics · doi:10.2147/tacg.s113310 · Cited by 70 · see citing works
Chronic liver disease in murine hereditary tyrosinemia type 1 induces resistance to cell death
Vogel, A., van den Berg, I. E. T., Al-Dhalimy, M., Groopman, J. D., Ou, C., Ryabinina, O. P., Iordanov, M. S., Finegold, M. J., & Grompe, M. (2004) · Hepatology · doi:10.1002/hep.20077 · Cited by 66 · see citing works
Tyrosinemia type I treated by NTBC: How does AFP predict liver cancer?
Koelink, C., van Hasselt, P. M., van der Ploeg, A., van den Heuvel‐Eibrink, M. M., Wijburg, F. A., Bijleveld, C. M. A., & van Spronsen, F. J. (2006) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2006.07.009 · Cited by 65 · see citing works
Outcome of tyrosinaemia type III
Ellaway, C. J., Holme, E., Standing, S., Preece, M. A., Green, A., Plöchl, E., Ugarte, M., Trefz, F. K., & Leonard, J. V. (2001) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1013936107064 · Cited by 65 · see citing works
Self-citation
Mutations in the 4-hydroxyphenylpyruvate dioxygenase gene ( HPD ) in patients with tyrosinemia type III
Rüetschi, U., Cerone, R., Pérez‐Cerdá, C., Schiaffino, M. C., Standing, S., Ugarte, M., & Holme, E. (2000) · Human Genetics · doi:10.1007/s004390000307 · Cited by 62 · see citing works
Self-citation
Newborn Screening for Hepatorenal Tyrosinemia: Tandem Mass Spectrometric Quantification of Succinylacetone
Sander, J., Janzen, N., Peter, M., Sander, S., Steuerwald, U., Holtkamp, U., Schwahn, B., Mayatepek, E., Trefz, F. K., & Das, A. M. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2005.059790 · Cited by 62 · see citing works
Metabolic Liver Disease in Children
Hansen, K., & Horslen, S. P. (2008) · Liver Transplantation · doi:10.1002/lt.21470 · Cited by 61 · see citing works
Long-Term Outcomes and Practical Considerations in the Pharmacological Management of Tyrosinemia Type 1
van Ginkel, W. G., Rodenburg, I. L., Harding, C. O., Hollak, C. E. M., Heiner-Fokkema, M. R., & van Spronsen, F. J. (2019) · Pediatric Drugs · doi:10.1007/s40272-019-00364-4 · Cited by 58 · see citing works
Neonatal Cholestasis
Lane, E. R., & Murray, K. F. (2017) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2017.01.006 · Cited by 56 · see citing works
Increase of CSF tyrosine and impaired serotonin turnover in tyrosinemia type I
Thimm, E., Herebian, D., Assmann, B., Klee, D., Mayatepek, E., & Spiekerkoetter, U. (2011) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2010.11.003 · Cited by 55 · see citing works
Therapeutic trials in the murine model of hereditary tyrosinaemia type I: A progress report
Grompe, M., Overturf, K., Al-Dhalimy, M., & Finegold, M. J. (1998) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1005462804271 · Cited by 54 · see citing works
Serum markers in alkaptonuria: simultaneous analysis of homogentisic acid, tyrosine and nitisinone by liquid chromatography tandem mass spectrometry
Hughes, A. T., Milan, A. M., Davison, A. S., Christensen, P. S., Ross, G. A., Gallagher, J. A., Dutton, J. J., & Ranganath, L. R. (2015) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563215571969 · Cited by 53 · see citing works
Structural insights of 4-Hydrophenylpyruvate dioxygenase inhibition by structurally diverse small molecules
Dong, J., Dong, J., Yu, X., Yan, Y.-C., Nan, J.-X., He, B., Ye, B.-Q., Yang, W., Lin, H., & Yang, G. (2022) · Advanced Agrochem · doi:10.1016/j.aac.2022.10.002 · Cited by 52 · see citing works
Liver transplantation for hereditary tyrosinemia type I: Analysis of the UNOS database
Arnon, R., Annunziato, R. A., Miloh, T., Wasserstein, M., Sogawa, H., Wilson, M., Suchy, F. J., & Kerkar, N. N. (2011) · Pediatric Transplantation · doi:10.1111/j.1399-3046.2011.01497.x · Cited by 52 · see citing works
Disorders of Tyrosine Metabolism
Chakrapani, A., & Holme, E. (2006) · Inborn Metabolic Diseases · doi:10.1007/978-3-540-28785-8_18 · Cited by 52 · see citing works
Self-citation
The Pathogenesis of Hepatocellular Carcinoma
Kirstein, M. M., & Vogel, A. (2014) · Digestive Diseases · doi:10.1159/000360499 · Cited by 51 · see citing works
In vivo suppressor mutations correct a murine model of hereditary tyrosinemia type I
Manning, K., Al-Dhalimy, M., Finegold, M. J., & Grompe, M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.21.11928 · Cited by 51 · see citing works
Neonatal hepatitis syndrome
Roberts, E. A. (2003) · Seminars in Neonatology · doi:10.1016/s1084-2756(03)00093-9 · Cited by 50 · see citing works
Ophthalmic follow‐up of patients with tyrosinaemia type I on NTBC
Gissen, P., Preece, M. A., Willshaw, H. A., & McKiernan, P. J. (2003) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1024011110116 · Cited by 49 · see citing works
Metabolic liver disease in children
Hansen, K., & Horslen, S. P. (2008) · Liver Transplantation · doi:10.1002/lt.21520 · Cited by 48 · see citing works
Cardiomyopathy in tyrosinaemia type I is common but usually benign
Arora, N., Stumper, O., Wright, J., Kelly, D. A., & McKiernan, P. J. (2006) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-006-0203-5 · Cited by 48 · see citing works
The Origin, Biology, and Therapeutic Potential of Facultative Adult Hepatic Progenitor Cells
Shin, S., & Kaestner, K. H. (2014) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/b978-0-12-416022-4.00010-x · Cited by 45 · see citing works
Clinical practice: NTBC therapy for tyrosinemia type 1: how much is enough?
El-Karaksy, H., Rashed, M., El-Sayed, R., El-Raziky, M., El-Koofy, N., El-Hawary, M., & Al-Dirbashi, O. (2010) · European Journal of Pediatrics · doi:10.1007/s00431-009-1090-1 · Cited by 45 · see citing works
The effect of nitisinone on homogentisic acid and tyrosine: a two-year survey of patients attending the National Alkaptonuria Centre, Liverpool
Milan, A. M., Hughes, A. T., Davison, A. S., Devine, J., Usher, J. L., Curtis, S., Khedr, M., Gallagher, J. A., & Ranganath, L. R. (2017) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563217691065 · Cited by 45 · see citing works
Liver Cancer in Tyrosinemia Type 1
van Ginkel, W. G., Pennings, J. P., & van Spronsen, F. J. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-55780-9_9 · Cited by 45 · see citing works
HCC prevalence and histopathological findings in liver explants of patients with hereditary tyrosinemia type 1
Neto, J. S., Leite, K. R. M., Porta, A., da Fonseca, E. A., Feier, F. H., Pugliese, R. P. S., Miura, I. K., Chapchap, P., & Porta, G. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25094 · Cited by 44 · see citing works
Long-term cognitive functioning in individuals with tyrosinemia type 1 treated with nitisinone and protein-restricted diet
García, M. I., Alicia De la Parra, C., Arias, C., Arredondo, M., & Cabello, J. F. (2017) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2017.01.016 · Cited by 43 · see citing works
Corneal opacities associated with NTBC treatment
Ahmad, S., Teckman, J. H., & Lueder, G. T. (2002) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(02)01532-5 · Cited by 43 · see citing works
Genetic and metabolic liver disease
Thompson, R. J., Portmann, B. C., & Roberts, E. A. (2011) · Elsevier eBooks · doi:10.1016/b978-0-7020-3398-8.00004-0 · Cited by 43 · see citing works
Current Strategies for the Treatment of Hereditary Tyrosinemia Type I
Ashorn, M. H., Pitkänen, S. T., Salo, M. K., & Heikinheimo, M. (2006) · Pediatric Drugs · doi:10.2165/00148581-200608010-00004 · Cited by 41 · see citing works
CRISPR/Cas9: at the cutting edge of hepatology
Pankowicz, F. P., Jarrett, K. E., Lagor, W. R., & Bissig, K. (2017) · Gut · doi:10.1136/gutjnl-2016-313565 · Cited by 43 · see citing works
Renal function in tyrosinaemia type I after liver transplantation: A long‐term follow‐up
Pierik, L. J. W. M., van Spronsen, F. J., Bijleveld, C. M. A., & van Dael, C. M. L. (2005) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-005-0059-0 · Cited by 40 · see citing works
Targeting glioma-initiating cells via the tyrosine metabolic pathway
Yamashita, D., Bernstock, J. D., Elsayed, G., Sadahiro, H., Mohyeldin, A., Chagoya, G., Ilyas, A., Mooney, J. H., Estévez-Ordoñez, D., Yamaguchi, S., et al. (2020) · Journal of neurosurgery · doi:10.3171/2019.11.jns192028 · Cited by 39 · see citing works
Splicing mutations, mainly IVS6-1(G>T), account for 70% of fumarylacetoacetate hydrolase (FAH) gene alterations, including 7 novel mutations, in a survey of 29 tyrosinemia type I patients
Arranz, J. A., Piñol, F., Kozák, L., Pérez‐Cerdá, C., Cormand, B., Ugarte, M., & Riudor, E. (2002) · Human Mutation · doi:10.1002/humu.10084 · Cited by 39 · see citing works
Spectrophotometric Microassay for δ-Aminolevulinate Dehydratase in Dried-Blood Spots as Confirmation for Hereditary Tyrosinemia Type I
Schulze, A., Frommhold, D., Hoffmann, G. F., & Mayatepek, E. (2001) · Clinical Chemistry · doi:10.1093/clinchem/47.8.1424 · Cited by 37 · see citing works
NTBC Treatment of the Pyomelanogenic Pseudomonas aeruginosa Clinical Isolate PA1111 Inhibits Pigment Production and Increases Sensitivity to Oxidative Stress
Ketelboeter, L. M., Potharla, V. Y., & Bardy, S. L. (2014) · Current Microbiology · doi:10.1007/s00284-014-0593-9 · Cited by 36 · see citing works
Extensive changes in liver gene expression induced by Hereditary Tyrosinemia type I are not normalized by treatment with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC)
Luijerink, M., Jacobs, S. M. M., van Beurden, E. A. C. M., Koornneef, L. P., Klomp, L. W. J., Berger, R., & van den Berg, I. E. T. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00433-1 · Cited by 36 · see citing works
Chimeric rodents with humanized liver: bridging the preclinical/clinical trial gap in ADME/toxicity studies
Foster, J. R., Lund, G. A., Sapelnikova, S., Tyrrell, D. L., & Kneteman, N. M. (2013) · Xenobiotica · doi:10.3109/00498254.2013.867553 · Cited by 35 · see citing works
Neurological and Neuropsychological Problems in Tyrosinemia Type I Patients
van Ginkel, W. G., Jahja, R., Huijbregts, S. C. J., & van Spronsen, F. J. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-55780-9_10 · Cited by 35 · see citing works
Alkaptonuria – Many questions answered, further challenges beckon
Davison, A. S., Hughes, A., Milan, A. M., Sireau, N. T., Gallagher, J. A., & Ranganath, L. R. (2019) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563219879957 · Cited by 36 · see citing works
New Management Options for End-Stage Chronic Liver Disease and Acute Liver Failure
Debray, D., Yousef, N., & Durand, P. (2006) · Pediatric Drugs · doi:10.2165/00148581-200608010-00001 · Cited by 35 · see citing works
Hepatic stress in hereditary tyrosinemia type 1 (HT1) activates the AKT survival pathway in the fah−/− knockout mice model
Orejuela, D., Jorquera, R., Bergeron, A., Finegold, M. J., & Tanguay, R. M. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2007.09.014 · Cited by 34 · see citing works
Hepatocellular carcinoma despite long‐term survival in chronic tyrosinaemia I
Kim, S. Z., Kupke, K. G., Ierardi-Curto, L. A., Holme, E., Greter, J., Tanguay, R. M., Poudrier, J., D’Astous, M., Lettre, F., Hahn, S. H., et al. (2000) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1026756501669 · Cited by 35 · see citing works
Self-citation
Reversible Keratopathy Due to Hypertyrosinaemia Following Intermittent Low-Dose Nitisinone in Alkaptonuria: A Case Report
Stewart, R. M. K., Briggs, M. C., Jarvis, J. C., Gallagher, J. A., & Ranganath, L. R. (2014) · JIMD Reports · doi:10.1007/8904_2014_307 · Cited by 34 · see citing works
Liver Transplantation for Metabolic Liver Diseases
Zhang, K. Y., Tung, B. Y., & Kowdley, K. V. (2007) · Clinics in Liver Disease · doi:10.1016/j.cld.2007.04.002 · Cited by 34 · see citing works
Reversibility of cirrhotic regenerative liver nodules upon NTBC treatment in a child with tyrosinaemia type I
Crone, J., Möslinger, D., Bodamer, O., Schima, W., Huber, W., Holme, E., & Ipsiroglu, S. S. (2003) · Acta Paediatrica · doi:10.1111/j.1651-2227.2003.tb02518.x · Cited by 34 · see citing works
Self-citation
Single dose NTBC‐treatment of hereditary tyrosinemia type I
Schlune, A., Thimm, E., Herebian, D., & Spiekerkoetter, U. (2012) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-012-9450-9 · Cited by 33 · see citing works
Hereditary tyrosinemia type 1 in T urkey: Twenty year single‐center experience
Zeybek, A. Ç. A., Kıykım, E., Soyuçen, E., Cansever, M. Ş., Altay, S., Zübarioğlu, T., Erkan, T., & Aydın, A. (2014) · Pediatrics International · doi:10.1111/ped.12503 · Cited by 33 · see citing works
Liver tumors in children with metabolic disorders.
Schady, D. A., Roy, A., & Finegold, M. J. (2015) · PubMed Central · doi:10.3978/j.issn.2224-4336.2015.10.08 · Cited by 33 · see citing works
Tissue distribution of 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione (NTBC) and its effect on enzymes involved in tyrosine catabolism in the mouse
Lock, E. A., Gaskin, P., Ellis, M. K., Provan, W. M., Robinson, M., & Smith, L. L. (2000) · Toxicology · doi:10.1016/s0300-483x(99)00205-x · Cited by 33 · see citing works
Nitisinone for the treatment of hereditary tyrosinemia type I
McKiernan, P. J. (2013) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2013.800807 · Cited by 32 · see citing works
Monitoring tyrosinaemia type I: Blood spot test for nitisinone (NTBC)
Sander, J., Janzen, N., Terhardt, M., Sander, S., Gökcay, G., Demirkol, M., Ozer, I., Peter, M., & Das, A. M. (2011) · Clinica Chimica Acta · doi:10.1016/j.cca.2010.09.027 · Cited by 32 · see citing works
Tyrosinemia Type 1: Metastatic Hepatoblastoma With a Favorable Outcome
Nobili, V., Jenkner, A., Francalanci, P., Castellano, A., Holme, E., Callea, F., & Dionisi‐Vici, C. (2010) · PEDIATRICS · doi:10.1542/peds.2009-1639 · Cited by 32 · see citing works
Self-citation
Spectroscopic and computational studies of NTBC bound to the non-heme iron enzyme (4-hydroxyphenyl)pyruvate dioxygenase: Active site contributions to drug inhibition
Neidig, M. L., Decker, A., Kavana, M., Moran, G. R., & Solomon, E. I. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.08.242 · Cited by 32 · see citing works
Indications for combined liver and kidney transplantation in children
Chava, S. P., Singh, B. B., Pal, S., Dhawan, A. K., & Heaton, N. D. (2009) · Pediatric Transplantation · doi:10.1111/j.1399-3046.2008.01046.x · Cited by 32 · see citing works
Inborn Errors of Metabolism
Trahms, C. M. (2001) · Elsevier eBooks · doi:10.1016/b978-012193155-1/50016-7 · Cited by 31 · see citing works
Disorders of phenylalanine and tyrosine metabolism
Alsharhan, H., & Ficicioglu, C. H. (2020) · Translational Science of Rare Diseases · doi:10.3233/trd-200049 · Cited by 30 · see citing works
1H NMR, 13C NMR, and Computational DFT Studies of the Structure of 2-Acylcyclohexane-1,3-diones and Their Alkali Metal Salts in Solution
Szczeciński, P., Gryff‐Keller, A., & Molchanov, S. (2006) · The Journal of Organic Chemistry · doi:10.1021/jo060583g · Cited by 30 · see citing works
Hepatocellular Carcinoma in Tyrosinemia Type 1 Without Clear Increase of AFP
van Ginkel, W. G., Gouw, A., van der Jagt, E. J., de Jong, K. P., Verkade, H. J., & van Spronsen, F. J. (2015) · PEDIATRICS · doi:10.1542/peds.2014-1913 · Cited by 29 · see citing works
Asymptomatic Corneal Keratopathy Secondary to Hypertyrosinaemia Following Low Dose Nitisinone and a Literature Review of Tyrosine Keratopathy in Alkaptonuria
Khedr, M., Judd, S., Briggs, M. C., Hughes, A. T., Milan, A. M., Stewart, R. M. K., Lock, E. A., Gallagher, J. A., & Ranganath, L. R. (2017) · JIMD Reports · doi:10.1007/8904_2017_62 · Cited by 28 · see citing works
Phenylalanine supplementation improves the phenylalanine profile in tyrosinaemia
Wilson, C. J., Wyk, K. G. V., Leonard, J. V., & Clayton, P. T. (2000) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1005666426079 · Cited by 29 · see citing works
Early effect of NTBC on renal tubular dysfunction in hereditary tyrosinemia type 1
Maiorana, A., Malamisura, M., Emma, F., Boenzi, S., Ciommo, V. M. D., & Dionisi‐Vici, C. (2014) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2014.07.021 · Cited by 29 · see citing works
Repurposing the orphan drug nitisinone to control the transmission of African trypanosomiasis
Sterkel, M., Haines, L. R., Casas-Sánchez, A., Adung’a, V. O., Vionette-Amaral, R. J., Quek, S., Rose, C., dos Santos, M. S., Escude, N. G., Ismail, H. M., et al. (2021) · PLoS Biology · doi:10.1371/journal.pbio.3000796 · Cited by 26 · see citing works
Pharmacological rescue of the 14CoS/14CoS mouse: hepatocyte apoptosis is likely caused by endogenous oxidative stress
Dieter, M. Z., Freshwater, S. L., Miller, M. L., Shertzer, H. G., Dalton, T. P., & Nebert, D. W. (2003) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(03)00273-9 · Cited by 27 · see citing works
Maternal and fetal tyrosinemia type I
Segarra, N. G., Roche, S., Imbard, A., Benoist, J., Grenèche, M. O., Spraul, A., & de Baulny, H. O. (2010) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-012-9569-8 · Cited by 27 · see citing works

Hepatocellular Carcinoma in Hereditary Tyrosinemia Type I Despite 2-(2 Nitro-4-3 Trifluoro- Methylbenzoyl)-1, 3-Cyclohexanedione Treatment
van Spronsen, F. J., Bijleveld, C. M. A., van Maldegem, B. T., & Wijburg, F. A. (2005) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/00005176-200501000-00017 · Cited by 92 · see citing works
Tyrosinemia type I: Case series with response to treatment to NTBC
Shah, I., & Shah, F. (2016) · Indian Journal of Gastroenterology · doi:10.1007/s12664-016-0650-3 · Cited by 4 · see citing works
Évolution favorable sous traitement par NTBC de l'insuffisance hépatique aiguë révélatrice de la tyrosinémie héréditaire de type I
Barkaoui, E., Debray, D., Habès, D., de Baulny, H. O., & Bernard, O. (1999) · Archives de Pédiatrie · doi:10.1016/s0929-693x(99)80562-4 · Cited by 10 · see citing works
NTBC treatment in tyrosinaemia type I: Long‐term outcome in French patients
Masurel‐Paulet, A., Poggi‐Bach, J., Rolland, M. ‐., Bernard, O., Guffon, N., Dobbelaere, D., Sarles, J., de Baulny, H. O., & Touati, G. (2008) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-008-0793-1 · Cited by 212 · see citing works
[Evolution of a case of tyrosinemia type I treated with NTBC].
Viladoms, J. R., Busca, M. A. V., Lambruschini Ferri, N., Mas Comas, A., Pascual, E. G., & Holme, E. (2001) · PubMed · Cited by 6 · see citing works
Self-citation

Authors: Holme, E., & Lindstedt, S.
Affiliations: Sahlgrenska University Hospital (SE)
Venue: Journal of Inherited Metabolic Disease
Publisher: Wiley
Published: 1998-08
Volume: 21
Issue: 5
Pages: 507-517
ISSN: 0141-8955 (ISSN-L)
1573-2665
DOI: 10.1023/a:1005410820201
OpenAlex: W1567009066
Cited by: 264
References: 17
Citations by year: 2026: 1 · 2025: 6 · 2024: 4 · 2023: 6 · 2022: 9 · 2021: 7 · 2020: 6 · 2019: 10 · 2018: 2 · 2017: 18 · 2016: 7 · 2015: 8 · 2014: 14 · 2013: 11 · 2012: 7
FWCI: 5.92
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Journal of Inherited Metabolic Disease (publishedVersion)
PubMed (publishedVersion)
Funders: Swedish Cancer Foundation
Vetenskapsrådet
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Neonatal Health and Biochemistry
Keywords: NTBC, tyrosine catabolism, hepatocellular carcinoma prevention, liver transplantation, succinylacetone, early treatment initiation, treatment response
MeSH terms: Amino Acid Metabolism, Inborn Errors, Animals, Clinical Trials as Topic, Cyclohexanones, Enzyme Inhibitors, Humans, Nitrobenzoates, Tyrosine, 4-Hydroxyphenylpyruvate Dioxygenase

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Tyrosinaemia type I and NTBC (2‐(2‐nitro‐4‐trifluoromethylbenzoyl)‐1,3‐cyclohexanedione)

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks